Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Allergan

Status: Completed

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Treatments: Drug: Bimatoprost 0.01% ophthalmic solution

Study type: Observational

Funder types: Industry

Identifiers

NCT01568008

MAF/AGN/OPH/GLA/031

Details and patient eligibility

About

This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.

Enrollment: 933 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of POAG or OHT
• Prescribed Lumigan® 0.01%

Exclusion criteria

• None

Trial design

933 participants in 1 patient group

All participants

Description:

Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.

Treatment:

Drug: Bimatoprost 0.01% ophthalmic solution